# EDGAR Filing Document

**Accession Number:** 0001873032
**File Stem:** 0001193125-26-054535
**Filing Date:** 2026-2
**Character Count:** 12795
**Document Hash:** 488c3fc6e1f44fa7b14dee80b075cd6e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-054535.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001193125-26-054535

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KESTRA MEDICAL TECHNOLOGIES, LTD.
- **CENTRAL INDEX KEY:** 0001877184
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95012
- **FILM NUMBER:** 26640601

**BUSINESS ADDRESS:**
- **STREET 1:** 3933 LAKE WASHINGTON BLVD NE
- **STREET 2:** SUITE 200
- **CITY:** KIRKLAND
- **STATE:** WA
- **ZIP:** 98033
- **BUSINESS PHONE:** (425) 279-8002

**MAIL ADDRESS:**
- **STREET 1:** 3933 LAKE WASHINGTON BLVD NE
- **STREET 2:** SUITE 200
- **CITY:** KIRKLAND
- **STATE:** WA
- **ZIP:** 98033
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Endeavour Medtech Growth II LP
- **CENTRAL INDEX KEY:** 0001873032

**ORGANIZATION NAME:**
- **EIN:** 981530409
- **STATE OF INCORPORATION:** Y7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** P.O. BOX 656, EAST WING, TRAFALGAR COURT
- **STREET 2:** LES BANQUES
- **CITY:** ST PETER PORT
- **PROVINCE COUNTRY:** Y7
- **BUSINESS PHONE:** 44 1481 749 714

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** P.O. BOX 656, EAST WING, TRAFALGAR COURT
- **STREET 2:** LES BANQUES
- **CITY:** ST PETER PORT
- **PROVINCE COUNTRY:** Y7

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Kestra Medical Technologies, Ltd.

**Title of Class of Securities:** Common Shares, par value $1.00  per share

**CUSIP Number:** G52441105

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech Growth II LP | Names of Reporting Persons<br>Endeavour Medtech Growth II LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2448942 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2448942 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.20% | Percent of Class Represented by Amount in Row (9)<br>4.20% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on December 11, 2025, with the Securities and Exchange Commission (the "Form 10-Q").

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech Growth II Parallel LP | Names of Reporting Persons<br>Endeavour Medtech Growth II Parallel LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2448942 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2448942 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.20% | Percent of Class Represented by Amount in Row (9)<br>4.20% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Form 10-Q.

---

| 1. | Names of Reporting Persons<br>Endeavour Medtech II GP Limited | Names of Reporting Persons<br>Endeavour Medtech II GP Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Y7 | Citizenship or Place of Organization<br>Y7 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>2448942 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>2448942 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2448942 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>4.20% | Percent of Class Represented by Amount in Row (9)<br>4.20% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Form 10-Q.

---

**Item 1(a). Name of Issuer:**
Kestra Medical Technologies, Ltd.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
3933 Lake Washington BLVD NE, Suite 200, Kirkland, WA 98003

**Item 2(a). Name of Person Filing:**
This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

(i)        Endeavour Medtech Growth II LP
(ii)       Endeavour Medtech Growth II Parallel LP
(iii)      Endeavour Medtech II GP Limited

**Item 2(b). Address of Principal Business Office:**
The address and principal business address of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St. Peter Port, Guernsey GY1 3PP.

**Item 2(c). Citizenship:**
Endeavour Medtech Growth II LP is a Guernsey limited partnership. Endeavour Medtech Growth II Parallel LP is a Guernsey limited partnership. Endeavour Medtech II GP Limited is a Guernsey company limited by shares.

**Item 2(d). Title of Class of Securities:**
Common Shares, par value $1.00  per share

**Item 2(e). CUSIP Number:**
G52441105

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

2,405,643 Common Shares are held of record by Endeavour Medtech Growth II LP and 43,299 Common Shares are held of record by Endeavour Medtech Growth II Parallel LP. Endeavour Medtech II GP Limited is the general partner of Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP. As a result of foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Persons may be deemed to share ownership over the reported 2,448,942 Common Shares, but the filing of this Statement shall not be deemed an admission of such beneficial ownership by any of the Reporting Persons for purposes of Section 13(d) or Section 13(g) or for any other purpose.

**(b) Percent of class:**

See responses to Item 11 on each cover page.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See responses to Item 5 on each cover page

**(ii) Shared power to vote or to direct the vote:**

See responses to Item 6 on each cover page.

**(iii) Sole power to dispose or to direct the disposition of:**

See responses to Item 7 on each cover page.

**(iv) Shared power to dispose or to direct the disposition of:**

See responses to Item 8 on each cover page.

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Endeavour Medtech Growth II LP**

**Date:** 02/17/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton / Director of Endeavour Medtech II GP Limited, its General Partner

**Endeavour Medtech Growth II Parallel LP**

**Date:** 02/17/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton / Director of Endeavour Medtech II GP Limited, its General Partner

**Endeavour Medtech II GP Limited**

**Date:** 02/17/2026

**By:** /s/ Nick Barton

**Name & Title:** Nick Barton / Director